FOXM1 and breast cancer: We demonstrate that recently discovered compounds that bind FOXM1 and trigger small-molecule–induced degradation via the proteasome (50) are effective across multiple models of luminal B–like breast cancer, establishing a potential indication for the clinical translation of these compounds.